Climb Bio Inc (NASDAQ: CLYM) kicked off on Friday, up 8.68% from the previous trading day, before settling in for the closing price of $2.19. Over the past 52 weeks, CLYM has traded in a range of $1.05-$8.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -40.44% over the last five years. While this was happening, its average annual earnings per share was recorded 51.47%. With a float of $58.65 million, this company’s outstanding shares have now reached $67.76 million.
Climb Bio Inc (CLYM) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Climb Bio Inc is 13.46%, while institutional ownership is 73.76%. The most recent insider transaction that took place on Jun 30 ’25, was worth 25,154. In this transaction President and CEO of this company sold 20,618 shares at a rate of $1.22, taking the stock ownership to the 48,132 shares. Before that another transaction happened on Jun 20 ’25, when Company’s SVP, Finance & CAO sold 1,242 for $1.24, making the entire transaction worth $1,540. This insider now owns 18,888 shares in total.
Climb Bio Inc (CLYM) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 51.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.29% during the next five years compared to -40.44% drop over the previous five years of trading.
Climb Bio Inc (NASDAQ: CLYM) Trading Performance Indicators
Take a look at Climb Bio Inc’s (CLYM) current performance indicators. Last quarter, stock had a quick ratio of 14.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.69, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.74 in one year’s time.
Technical Analysis of Climb Bio Inc (CLYM)
Analysing the last 5-days average volume posted by the [Climb Bio Inc, CLYM], we can find that recorded value of 0.96 million was better than the volume posted last year of 0.35 million. As of the previous 9 days, the stock’s Stochastic %D was 92.43%.
During the past 100 days, Climb Bio Inc’s (CLYM) raw stochastic average was set at 97.08%, which indicates a significant increase from 95.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.16 in the past 14 days, which was higher than the 0.11 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.50, while its 200-day Moving Average is $1.76. Now, the first resistance to watch is $2.48. This is followed by the second major resistance level at $2.57. The third major resistance level sits at $2.73. If the price goes on to break the first support level at $2.23, it is likely to go to the next support level at $2.07. Should the price break the second support level, the third support level stands at $1.98.
Climb Bio Inc (NASDAQ: CLYM) Key Stats
The company with the Market Capitalisation of 161.27 million has total of 67,764K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -73,900 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -8,670 K.
